Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jakub, Trefler"'
Autor:
Edward Keystone, Josef S Smolen, Gerd R Burmester, Slawomir Jeka, Pawel Hrycaj, Janusz Jaworski, Anna Dudek, Artur Racewicz, Agnieszka Zielinska, YunJu Bae, Rafal Wojciechowski, Marek Krogulec, Jakub Trefler, Katarzyna Kolossa, Magdalena Krajewska-Włodarczyk, Piotr Adrian Klimiuk, SungHyun Kim, GoEun Yang, YooBin Jung, JiWoo Hong
Publikováno v:
RMD Open, Vol 10, Iss 4 (2024)
Objectives To demonstrate efficacy equivalence of CT-P47 and EU-approved reference tocilizumab (r-TCZ) in patients with rheumatoid arthritis (RA).Methods This double-blind, phase III study randomised (1:1) patients to receive CT-P47 or r-TCZ (8 mg/kg
Externí odkaz:
https://doaj.org/article/57062166f2dd4fe39a65b97114a32a54
Autor:
Jonathan Kay, Janusz Jaworski, Rafal Wojciechowski, Piotr Wiland, Anna Dudek, Marek Krogulec, Slawomir Jeka, Agnieszka Zielinska, Jakub Trefler, Katarzyna Bartnicka-Maslowska, Magdalena Krajewska-Wlodarczyk, Piotr A. Klimiuk, Sang Joon Lee, Yun Ju Bae, Go Eun Yang, Jae Kyoung Yoo, Daniel E. Furst, Edward Keystone
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-12 (2021)
Abstract Background To demonstrate equivalent efficacy of the proposed high-concentration (100 mg/ml), citrate-free adalimumab biosimilar CT-P17 to European Union-approved adalimumab (EU-adalimumab) in subjects with active rheumatoid arthritis (RA).
Externí odkaz:
https://doaj.org/article/6b49e98734e7429687859127a57bc3fa
Autor:
Vyacheslav Zhdan, Sunghyun Kim, Rene Westhovens, Jee Hye Suh, Piotr Wiland, Janusz Jaworski, Seul Gi Lee, Marek Zawadzki, Pavel Shesternya, Roman Yatsyshyn, Delina Ivanova, Sergii Shevchuk, Paweł Hrycaj, Elias Chalouhi El-Khouri, Mykola Stanislavchuk, Éva Balázs, Alfredo Berrocal Kasay, Larisa Eliseeva, Dae Hyun Yoo, Sang Joon Lee, Noo Ri Han, Jakub Trefler
Publikováno v:
Rheumatology (Oxford, England)
Objective To assess non-inferiority of s.c. to i.v. CT-P13 in RA. Methods Patients with active RA and inadequate response to MTX participated in this phase I/III double-blind study at 76 sites. Patients received CT-P13 i.v. 3 mg/kg [week (W) 0 and W2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc4871ed28ea4b0d6664335b94ef1675
http://europepmc.org/articles/PMC8121438
http://europepmc.org/articles/PMC8121438
Autor:
Sung Hyun Kim, Go Eun Yang, Marek Krogulec, Janusz Jaworski, Sang Joon Lee, Jonathan Kay, Anna Dudek, Edward C. Keystone, Yun Ju Bae, Jae Kyoung Yoo, Piotr Adrian Klimiuk, Piotr Wiland, Rafał Wojciechowski, Daniel E. Furst, Sławomir Jeka, Magdalena Krajewska-Włodarczyk, Jakub Trefler, Agnieszka Zielińska, Katarzyna Bartnicka-Maslowska
Publikováno v:
Rheumatology (Oxford, England). 61(4)
Objective To compare the safety and efficacy of switching from reference adalimumab to adalimumab biosimilar CT-P17 with continuing reference adalimumab/CT-P17 in active RA. Methods This double-blind, phase III study randomized (1:1) subjects with ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc903606c0634f5a88282630baf45975
https://pubmed.ncbi.nlm.nih.gov/34559204
https://pubmed.ncbi.nlm.nih.gov/34559204
Autor:
Katarzyna Bartnicka-Maslowska, Jae Kyoung Yoo, Piotr Wiland, Magdalena Krajewska-Włodarczyk, Jakub Trefler, Yun Ju Bae, Jonathan Kay, Agnieszka Zielińska, Go Eun Yang, Janusz Jaworski, Sławomir Jeka, Daniel E. Furst, Rafał Wojciechowski, Sang Joon Lee, Anna Dudek, Marek Krogulec, Edward C. Keystone, Piotr Adrian Klimiuk
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-12 (2021)
Arthritis Research & Therapy
Arthritis Research & Therapy
Background To demonstrate equivalent efficacy of the proposed high-concentration (100 mg/ml), citrate-free adalimumab biosimilar CT-P17 to European Union-approved adalimumab (EU-adalimumab) in subjects with active rheumatoid arthritis (RA). Methods T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cabcce7cfdd984768e84738fd71a94c
https://doi.org/10.1186/s13075-020-02394-7
https://doi.org/10.1186/s13075-020-02394-7
Autor:
Agnieszka Paradowska-Gorycka, Jakub Trefler, Jan K. Lacki, E. Wojtecka-Lukasik, B. Wojciechowska, S. Maslinski
Publikováno v:
Scandinavian Journal of Immunology. 72:134-141
Interleukin-17F (IL-17F) is a novel proinflammatory cytokine. IL-17F gene is an excellent candidate for chronic inflammatory disease. We investigated the association between rheumatoid arthritis (RA) and His161Arg (7488A/G; rs763780) and Glu126Gly (7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2f44f29b2a5e813f8cc7609cb82ec7d
https://doi.org/10.1111/j.1365-3083.2010.02411.x
https://doi.org/10.1111/j.1365-3083.2010.02411.x
Publikováno v:
International Journal of Immunogenetics. 37:225-231
Interleukin (IL)-10 is an important multifunctional cytokine with both anti-inflammatory and immunoregulatory effects in rheumatoid arthritis (RA). In the present study, we evaluated the frequency and potential impact of IL-10 promoter polymorphisms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81e9f8d2219d2be9c2f1cd477afba733
https://doi.org/10.1111/j.1744-313x.2010.00913.x
https://doi.org/10.1111/j.1744-313x.2010.00913.x
Publikováno v:
Clinical Rheumatology. 27:565-572
Rheumatoid arthritis (RA) is frequently complicated by peri-articular and generalized osteoporosis due to increased bone resorption by activated osteoclasts. Pro-inflammatory cytokines, such as TNF-alpha, interleukin 1 (IL1), and interleukin 6 (IL6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84b3af4a1c8b2b5c73ef22bad0b90794
https://doi.org/10.1007/s10067-007-0747-2
https://doi.org/10.1007/s10067-007-0747-2
Publikováno v:
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego. 27(158)
In our previous paper we have presented recent advances in the knowledge of the genetic risk factors predisposing to rheumatoid arthritis development. In contrast to the progress that has been made in identification of genes responsible for susceptib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b9fcf6f87342b2efa9051d7e9e008c40
https://pubmed.ncbi.nlm.nih.gov/19856887
https://pubmed.ncbi.nlm.nih.gov/19856887
Publikováno v:
Wiadomosci lekarskie (Warsaw, Poland : 1960). 60(9-10)
Rheumatoid arthritis (RA) is a chronic, inflammatory, autoimmune disease leading to severe disability. A secondary amyloidosis (AA amyloidosis) affecting RA patient is a life threatening clinical complication of the illness. The most common symptoms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::aeab71a3a0289c4030369a9574cc3778
https://pubmed.ncbi.nlm.nih.gov/18350722
https://pubmed.ncbi.nlm.nih.gov/18350722